Swiss National Bank Sells 1,300 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Swiss National Bank lowered its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 248,600 shares of the biopharmaceutical company’s stock after selling 1,300 shares during the quarter. Swiss National Bank’s holdings in Halozyme Therapeutics were worth $14,230,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Congress Asset Management Co. raised its holdings in shares of Halozyme Therapeutics by 446.5% in the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after purchasing an additional 1,988,238 shares in the last quarter. Handelsbanken Fonder AB raised its stake in shares of Halozyme Therapeutics by 76.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock worth $112,715,000 after acquiring an additional 856,200 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Halozyme Therapeutics by 12.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after acquiring an additional 209,530 shares in the last quarter. Epoch Investment Partners Inc. raised its stake in shares of Halozyme Therapeutics by 23.3% during the 1st quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company’s stock worth $58,319,000 after acquiring an additional 270,579 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in shares of Halozyme Therapeutics by 9.7% during the 2nd quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company’s stock worth $43,002,000 after acquiring an additional 72,544 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on HALO. TD Cowen boosted their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Piper Sandler boosted their price objective on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. Morgan Stanley boosted their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their target price for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $61.11.

Halozyme Therapeutics Stock Up 7.2 %

HALO stock opened at $49.00 on Friday. The firm’s fifty day simple moving average is $54.85 and its 200-day simple moving average is $53.42. The company has a market capitalization of $6.23 billion, a P/E ratio of 16.23, a price-to-earnings-growth ratio of 0.41 and a beta of 1.29. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53.

Insider Activity

In other news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $59.09, for a total value of $590,900.00. Following the sale, the chief executive officer now directly owns 676,744 shares of the company’s stock, valued at $39,988,802.96. This represents a 1.46 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 60,000 shares of company stock valued at $3,425,000 in the last ninety days. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.